CABA - CIK 0001759138
The table below shows Cabaletta Bio, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $142.67M | $97.20M | $55.42M | $39.30M | $32.49M | $21.38M |
| SG&A | $29.57M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $27.94M |
| $19.24M |
| $14.84M |
| $13.82M |
| $12.46M |
| Operating income | -$172.24M | -$125.14M | -$74.66M | -$54.14M | -$46.31M | -$33.83M |
| Income tax | $0.00 | $0.00 | - | - | - | - |
| Net income | -$167.86M | -$115.86M | -$67.68M | -$52.98M | -$46.29M | -$33.34M |
| EPS (diluted) | -$2.10 | -$2.34 | -$1.65 | -$1.81 | -$1.80 | - |